Accepted Article
Mesalamine-induced myopericarditis - A case report

Sónia Bernardo, Samuel Raimundo Fernandes, Luís Araújo-Correia

DOI: 10.17235/reed.2016.4016/2015
Link: PDF


This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Mesalamine-induced myopericarditis - A case report

Sónia Bernardo, Samuel Raimundo Fernandes and Luís Araújo-Correia

Gastroenterology and Hepatology Department. Hospital Santa Maria. Centro Hospitalar Lisboa Norte. Lisbon, Portugal

Received: 27/09/15
Accepted: 29/09/15
Correspondence: Sónia Bernardo. Gastroenterology and Hepatology Department. Hospital Santa Maria. Centro Hospitalar Lisboa Norte. Av. Prof. Egas Moniz. 1649-035 Lisbon, Portugal
e-mail: soniamcb@hotmail.com

ABSTRACT
Myopericarditis has occasionally been reported as a side effect of mesalamine in patients with inflammatory bowel disease. We present a 20-year-old woman with ulcerative colitis admitted with chest pain. After thorough investigation she was diagnosed with myopericarditis potentially related to mesalamine. There was complete clinical and laboratorial recovery following drug withdrawal. Although uncommon, the possibility of myopericarditis should be considered in patients with inflammatory bowel disease presenting with cardiac complaints. Early recognition can avoid potential life-threatening complications.

Key words: Messalamine. Ulcerative colitis. Myopericarditis.

INTRODUCTION
Myopericarditis represents an inflammatory process affecting the heart muscle and pericardium. Acute pericarditis is responsible for up to 5% of admissions to the emergency department and may result from drugs, infections and autoimmune or idiopathic disorders (1). Several factors may be responsible for extraintestinal organ involvement in inflammatory bowel disease (IBD) and sometimes it can be difficult to differentiate the true extraintestinal manifestations, i.e., primary systemic affection by the disease itself, from secondary extraintestinal complications of the disease, caused by malnutrition, chronic inflammation or therapy side effects (2). Although uncommon, cardiac involvement has been reported in patients with IBD, especially in ulcerative colitis (UC) (3-5). Mesalamine is the standard treatment for patients with mild to moderate UC. Although uncommon, cardiac adverse events have been reported in patients taking mesalamine, including pericarditis, myocarditis and conduction defects (6). In this paper, we report a case of myopericarditis induced by mesalamine in a patient with UC. We appraise the clinical and laboratorial findings, discuss treatment and prognosis, and review the available literature.

CASE REPORT
We report the case of a 20-year-old woman admitted with asthenia, myalgia, arthralgia and chest pain. Her medical history was relevant for mild ulcerative proctitis diagnosed 4 years before. Her family history was significant for IBD (paternal uncle). Due to a recent flare, the patient had been started on oral (3g/day) and topical (3g/week) mesalamine with good response. Two weeks before, she started complaining of asthenia, myalgia and arthralgia involving the wrists and lower back. In the following week, she developed retrosternal discomfort and palpitations. Her physical examination did not show any relevant findings including fever, lymphadenopathies, rash, arthritis or heart murmurs. Her abdominal examination was unremarkable. Blood analysis showed normal white blood cells of $7.82 \times 10^9$ (4.0-11.0 $\times 10^9$) with mild eosinophilia (820 eosinophils) and elevated C-reactive protein (CRP) of 1.77 mg/dl (< 0.5 mg/dl). There was also a slight elevation of creatine-kinase (CK) - 510 (< 211 U/L), CK-MB - 587 (< 360 U/L) and lactate dehydrogenase - 418 (< 372 U/L). Troponin I was within normal range - 0.01 (< 0.07 µg/L). Both electrocardiogram and echocardiogram
showed no relevant findings. An extensive workup including chest CT, articular X-ray, electromyogram and autoimmune and microbiologic studies failed to show an etiology for her disease (Table I). A presumptive diagnosis of idiopathic myopericarditis was assumed and the patient was discharged with symptomatic therapy. The patient restarted mesalamine. She returned to our emergency department two days later with the same complaints. A recap of her medical history showed that mesalamine was a drug potentially involved. After exclusion of other causes, we assumed the diagnosis of mesalamine-induced myopericarditis. Mesalamine was stopped and the patient started on oral prednisolone and azathioprine, with clinical and laboratorial resolution (Table II). Follow-up cardiac magnetic resonance revealed no abnormalities (Fig. 1). The patient remains asymptomatic and in clinical remission of her UC.

**DISCUSSION**

It is estimated that 25% to 36% of patients with IBD will present at least one extraintestinal manifestation (3). Among cardiologic complications, acute pericarditis appears to be the most common one, accounting for up to 70% of the reported cases (6). Cardiac complications are independent of the bowel disease and the natural history may be highly variable with recurrent episodes having been reported (4). The incidence of myopericarditis appears to be similar between genders (5). As mentioned above, drugs can be involved in the pathogenesis of IBD related cardiac manifestations. It must be noted that most reports of myopericarditis complicating IBD involve concomitant aminosalicylate therapy, making it difficult to exclude a drug-related effect (7-10). Several mechanisms have been proposed for mesalamine-induced myopericarditis: a) IgE-mediated allergic reaction; b) direct cardiac toxicity; c) cell-mediated hypersensitivity; and d) humoral antibody response. The theory involving cross-reactivity between antibodies produced against mesalamine and the myocardium tissues is considered as the most credible one (7-9). In our case, eosinophilia may have been related to a hypersensitivity reaction. Clinical manifestations typically occur within 2-4 weeks of drug initiation (7,8), but they may occur as early as 48 hours or after years of treatment (11,12). Curiously, steroids may delay the onset of manifestations (7). Withdrawal of mesalamine usually results in
resolution of clinical manifestations over 7 to 14 days. Reintroduction of mesalamine can lead to repeated episodes. This holds true regardless of the dose and route of administration (4,13). In one report, pericarditis developed when changing the route of administration of mesalamine from oral to rectal treatment (14). In our case myopericarditis was confirmed by clinical presentation and elevation of cardiac enzymes. After excluding other possible causes, including another autoimmune disorders and viral and bacterial infections, myopericarditis-induced by mesalamine was assumed. In the cases previously described as being the result of medication, there is in fact, as in our case, a clinical and laboratorial resolution with the discontinuation of the therapy, suggesting a cause-effect relationship. The recommended treatment of myopericarditis includes non-steroid anti-inflammatory drugs or steroids (11). Our patient was also started on steroids for control of the UC disease. The intolerance to mesalamine forced us to start azathioprine in order to maintain the patient in remission. Nevertheless, this puts our patient with mild proctitis at risk for azathioprine related side-effects and complications, namely infections and cancer. In conclusion, we report a case of mesalamine-induced myopericarditis successfully managed by drug discontinuation and steroids. Myopericarditis should always be considered in the differential diagnosis of chest pain. In addition, this important side-effect should be considered when administering 5-amynosalicilate compounds.

REFERENCES
4. Freeman HJ, Salh B. Recurrent myopericarditis with extensive ulcerative colitis. The Canadian Journal of Cardiology 2010;549-50. DOI: 10.1016/S0828-282X(10)70470-
<table>
<thead>
<tr>
<th>ANAs (titer)</th>
<th>1:60</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anti-sDNA, HLAB27, ANCA, ASMA, anti-SSA, anti-SSB, anti-RNP, anti-scl70, anti-JO1</strong></td>
<td>Negative</td>
</tr>
<tr>
<td><strong>Cytomegalovirus</strong></td>
<td>IgG+, IgM-</td>
</tr>
<tr>
<td><strong>Parvovirus</strong></td>
<td>IgG+, IgM-</td>
</tr>
<tr>
<td><strong>Herpes virus type I</strong></td>
<td>IgG+, IgM-</td>
</tr>
</tbody>
</table>

**ANA:** Antinuclear antibody; **anti-sDNA:** Anti-double stranded DNA antibody; **HLAB27:** Human leukocyte antigen B27; **ANCA:** Anti-neutrophil cytoplasmic antibody; **ASMA:** Anti-smooth muscle antibody; **anti-SSA and SSB:** Sjögren’s-syndrome-related antigen A and B antibody; **anti-RNP:** Small nuclear ribonucleoprotein antibody; **anti-scl70:** Anti-topoisomerase I antibody; **anti-JO1:** Aminoacyl-tRNA synthetases antibody.
Table II. Laboratorial evolution showing rapid improvement of laboratory tests

Prednisolone

CK: Creatine kinase; CK-MB: Creatine kinase MB isoenzyme; LDH: Lactate dehydrogenase.

Fig. 1.